Evidence map›Paper›PMID 42234171›Full record

ArticleRheumatology international2026

Myocarditis in idiopathic inflammatory myopathies: serologic and clinical correlates in a single-center registry.

Jorge Álvarez-Troncoso, Elena Refoyo-Salicio, Samuel Díaz-Planellas, Sergio Carrasco-Molina, Clara Soto-Abánades, Elena Martínez-Robles, Belén Gutiérrez-Sancerni, Ángel Robles-Marhuenda, Ana Noblejas-Mozo, Juan José Ríos-Blanco

Abstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jorge Álvarez-TroncosoSystemic Immune-Mediated Diseases Unit, Internal Medicine Department, Hospital Universitario La Paz, IDIPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain. jorge.alvarez.troncoso@gmail.com.ORCID http://orcid.org/0000-0003-1108-9461
Elena Refoyo-SalicioCardiology Department, Hospital Universitario La Paz, IDIPAZ, Madrid, Spain.ORCID http://orcid.org/0000-0003-4910-9827
Samuel Díaz-PlanellasSystemic Immune-Mediated Diseases Unit, Internal Medicine Department, Hospital Universitario La Paz, IDIPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.ORCID http://orcid.org/0009-0000-7160-4483
Sergio Carrasco-MolinaSystemic Immune-Mediated Diseases Unit, Internal Medicine Department, Hospital Universitario La Paz, IDIPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.ORCID http://orcid.org/0000-0002-5379-1665
Clara Soto-AbánadesSystemic Immune-Mediated Diseases Unit, Internal Medicine Department, Hospital Universitario La Paz, IDIPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.ORCID http://orcid.org/0009-0001-6544-0969
Elena Martínez-RoblesSystemic Immune-Mediated Diseases Unit, Internal Medicine Department, Hospital Universitario La Paz, IDIPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.ORCID http://orcid.org/0009-0002-6506-8746
Belén Gutiérrez-SancerniSystemic Immune-Mediated Diseases Unit, Internal Medicine Department, Hospital Universitario La Paz, IDIPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.ORCID http://orcid.org/0009-0002-7119-6808
Ángel Robles-MarhuendaSystemic Immune-Mediated Diseases Unit, Internal Medicine Department, Hospital Universitario La Paz, IDIPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.ORCID http://orcid.org/0000-0003-1156-2570
Ana Noblejas-MozoSystemic Immune-Mediated Diseases Unit, Internal Medicine Department, Hospital Universitario La Paz, IDIPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.ORCID http://orcid.org/0000-0003-1282-6515
Juan José Ríos-BlancoSystemic Immune-Mediated Diseases Unit, Internal Medicine Department, Hospital Universitario La Paz, IDIPAZ, Paseo de la Castellana, 261, 28046, Madrid, Spain.ORCID http://orcid.org/0000-0001-5257-6042

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To characterize the clinical and serological correlates of cardiovascular magnetic resonance (CMR)-confirmed myocarditis in idiopathic inflammatory myopathies (IIM), evaluate the diagnostic performance of high-sensitivity cardiac troponin I (hs-TnI), and quantify the independent prognostic impact of myocarditis relative to interstitial lung disease (ILD). Single-center retrospective cohort study (STROBE-compliant) of 142 consecutive adults with IIM (2019-2025). Myocarditis was confirmed by CMR according to the 2018 Lake Louise Criteria, performed both at diagnosis and during follow-up (with or without immunosuppression) upon clinical suspicion and/or elevated hs-TnI. Myositis-specific antibodies (MSA), myositis-associated antibodies (MAA), anti-Ro52 and antiphospholipid antibodies (aPL, Sydney criteria: ≥40 GPL/MPL units confirmed at ≥ 12 weeks) were systematically recorded. Associations were assessed with Fisher's exact test and logistic regression; multivariable models were pre-specified as parsimonious (two predictors) given the limited event count. Overall survival was analyzed with Kaplan-Meier curves, the log-rank test and Cox proportional-hazards regression. Myocarditis was confirmed in 9/142 patients (6.3%), without significant association with IIM class (P = 0.303) or with the antisynthetase antibody subgroup (anti-Jo-1 + PL-12 + PL-7 + EJ; 5.8% vs. 6.7%, P = 1.000). In univariable analyses, myocarditis was associated with Raynaud phenomenon (OR 13.6, 95% CI 2.3-80.0), aPL positivity (OR 10.7, 95% CI 2.6-43.9), anti-Ro52 coexisting with MSA/MAA (OR 8.7, 95% CI 2.2-34.8), anti-PM/Scl (OR 7.1, 95% CI 1.6-30.3), fever (OR 7.1, 95% CI 1.6-30.3) and ILD (OR 4.7, 95% CI 1.1-20.3). hs-TnI was markedly higher in myocarditis (median 366 vs. 3.5 ng/L; P < 0.001) with an area under the receiver-operating characteristic curve (AUROC) of 0.91 (95% CI 0.83-0.98). In the event-constrained multivariable model, Raynaud phenomenon (adjusted OR 13.1, 95% CI 1.5-112.7) and aPL (adjusted OR 7.2, 95% CI 1.4-36.0) remained independently associated. All-cause mortality was higher in myocarditis (44% vs. 9%; OR 7.95, 95% CI 2.0-31.5; log-rank P = 0.030; univariable Cox HR 3.77, 95% CI 1.03-13.78; P = 0.044), and persisted after adjustment for ILD in the logistic model (adjusted OR 5.9, 95% CI 1.3-26.1; P = 0.020), whereas ILD attenuated to a non-significant trend (adjusted OR 2.9, 95% CI 0.9-9.2; P = 0.073). In this single-center retrospective cohort, IIM-associated myocarditis was consistently associated with Raynaud phenomenon, aPL positivity and anti-Ro52 coexistence, and was associated with higher mortality than ILD. These findings support hs-TnI-guided triage to CMR as part of systematic cardiac surveillance in IIM, pending multicenter confirmation.

Indexed as

MyocarditisMyositisTroponin IAdultAgedAntibodies, AntiphospholipidAutoantibodiesBiomarkersFemaleHumansLung Diseases, InterstitialMagnetic Resonance ImagingMaleMiddle AgedPrognosisRegistriesAntibodies, AntiphospholipidAutoantibodiesBiomarkersTroponin IAntiphospholipid syndromeAutoantibodiesMagnetic resonance imaging, cineMortalityMyocarditisMyositisRaynaud diseaseTroponin I

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.